Drug Trial Radar · NCT05779267
NRX-101 Expanded Access
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- NeuroRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 22, 2023
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical trial. The objective of the program is to provide treatment access while monitoring safety in the context of NRX-101 administration paired with theta burst transcranial magnetic stimulation..
Conditions
- Treatment-Resistant Depression
Interventions
NRX-101Drug
D-cycloserine/lurasidone fixed dose combination
Transcranial Magnetic Stimulation ShamDevice
transcranial magnetic stimulation will be employed and has shown effect in this population
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harvard Mclean Hospital
Belmont, Massachusetts · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.